Abinopharm, Inc.

What Abinopharm, Inc. does

Abinopharm, Inc. is a privately held, science-driven pharmaceutical and nutraceutical company founded in 2020 and headquartered in Shelton, Connecticut. The company organizes operations around three business areas: Pharmaceuticals (active pharmaceutical ingredients with FDA-reviewed DMFs, generic drug products including ANDAs and 505(b)(2) NDAs, biosimilars, and 503B compounding of NAD+, NMN, and NR IV products), Nutritionals (bulk nutraceutical ingredients and dietary supplements sold under the AbinoNutra and Dr.Ergo brands), and Research & Development (drug discovery programs AP10001 and AP10002 targeting rare diseases, plus a Personalized Health Management Platform). Its two flagship ingredients are AbinoNutra NMN (β-Nicotinamide Mononucleotide, >99.0% purity, >100 tons annual capacity, produced via natural enzymatic fermentation in an FDA-registered cGMP facility with AS-GRAS certification) and Dr.Ergo L-Ergothioneine (>99.9% purity, FDA GRAS status, patented non-hygroscopic crystal structure, manufactured under licensed enzymatic fermentation technology from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences).

The company monetizes through a diversified B2B and DTC mix: direct enterprise sales of APIs and bulk ingredients to generic and biopharmaceutical firms, dietary supplement brands, formulators, and cosmetic companies; out-licensing of generic, biosimilar, and new chemical entity drug products globally; wholesale distribution and private-label services for AbinoNutra dietary supplements; direct-to-consumer e-commerce via the ambrosiaz.com storefront for branded NMN delayed-release capsules; 503B compounding distribution; and regulatory consulting covering DMF, ANDA, GRAS, and NDI dossier preparation. Pricing for APIs, bulk nutraceuticals, and drug products is quote-based and not publicly disclosed; consumer supplements are unit-priced with 300 mg delayed-release capsules sold in 60-count bottles. Customers are segmented into dietary supplement brands and formulators (primary), generic and biopharmaceutical firms, academic research institutions including the National University of Singapore, and individual longevity-focused consumers.

Scientific credibility is anchored by peer-reviewed human clinical trials published in GeroScience (2023, 2025) and Mechanisms of Ageing and Development (2024) at 300, 600, and 900 mg daily doses, with reported outcomes including up to 4.7-fold NAD+ elevation, 4.1–6.7 year biological age reduction, and favorable safety. The company was awarded the 2024 Outstanding Original Research Paper 3rd Prize by the American Aging Association and maintains strategic collaborations with Professor Andrea Maier at NUS, Professor Barry Halliwell, EGT-Synbio, and the Shanghai Institute of Organic Chemistry. Products are marketed in the United States, Japan, and Singapore with active clinical programs in Taiwan, Japan, and Singapore; the founder and CEO is Lin Yi.

Name

Abinopharm, Inc.

Legal name

Abinopharm, Inc.

Website

https://abinopharm.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Abinopharm, Inc. is a Shelton, Connecticut-based pharmaceutical and nutraceutical company that develops APIs, generic and biosimilar drug products, and longevity-focused ingredients (AbinoNutra NMN and Dr.Ergo L-Ergothioneine) for dietary supplement brands, cosmetic firms, and pharmaceutical customers via B2B sales, licensing, compounding, and DTC e-commerce.

Ownership category

akta.pro rank

Product category

Nutraceutical Ingredients

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical API manufacturing
• Nutraceutical ingredients supply
• Dietary supplement products
• Drug product licensing
• Regulatory consulting services

Headquarters

HQ city

Shelton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) Sales: Commercial APIs with DMF reviewed by US FDA and EU authorities. Manufacturing facilities passed authority inspections. Includes generics and specialty pharmaceutical ingredients.
2. Nutraceutical Ingredients: Sale of pharmaceutical-grade NMN bulk powder (AbinoNutra) and L-Ergothioneine (Dr.Ergo) bulk ingredients to dietary supplement and cosmetic industries.
3. Dietary Supplements: Sale of branded AbinoNutra dietary supplements including NMN delayed-release capsules through e-commerce and wholesale channels.
4. Drug Product Licensing & Collaboration: In- and out-licensing of pharmaceutical products worldwide including generics (ANDA and 505(b)(2) NDA), biosimilars, and new chemical entities (NCE).
5. Regulatory Consulting Services: Regulatory consulting including GRAS dossier preparation, FDA submissions, DMF dossier preparation, ANDA dossiers, and responses to deficiency letters.
6. Compounding Pharmaceuticals: Development, manufacturing, and distribution of compounded pharmaceutical products (NAD IV, NMN IV, NR IV) in compliance with US FDA 503B regulatory guidelines.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Abinopharm, Inc. develops, manufactures, and distributes active pharmaceutical ingredients (APIs), generic and biosimilar drug products, compounded pharmaceuticals, and longevity-focused nutraceutical ingredients (AbinoNutra NMN, Dr.Ergo L-Ergothioneine) and branded dietary supplements. The company also offers drug product licensing, regulatory consulting, drug discovery, and a personalized health management platform.

Product overview

Abinopharm, Inc. is a science-driven healthy longevity company with three primary business areas: Pharmaceuticals (API sourcing, drug products, compounding), Nutritionals (nutraceutical ingredients and dietary supplements), and Research & Development (drug discovery, personalized health management). The core product portfolio centers on AbinoNutra® branded ingredients and supplements for healthy longevity, including NMN (β-Nicotinamide Mononucleotide) and L-Ergothioneine (Dr.Ergo®), both supported by human clinical trials. The pharmaceutical division offers commercial and pipeline APIs, generic drugs, and biosimilars. The R&D division develops novel anti-aging drug candidates (AP10001, AP10002) and a personalized health management platform.

Differentiator

Problem solved

Functional benefit

Brands

• AbinoNutra® NMN: Award-winning NMN ingredient brand for healthy longevity, validated by human clinical trials for NAD+ support.
• Dr.Ergo® L-Ergothioneine

Products and services

• AbinoNutra NMN Bulk Powder Pharmaceutical-grade NMN (β-Nicotinamide Mononucleotide) bulk powder ingredient for NAD+ support and healthy longevity. Produced via natural enzymatic fermentation in FDA-registered cGMP facility with purity exceeding 99.0% and annual production capacity exceeding 100 tons. Sold B2B to dietary supplement brands, formulators, and cosmetic companies.
• AbinoNutra NMN Delayed Release Capsules AbinoNutra NMN dietary supplement in delayed-release capsules, 300mg per capsule, 60 capsules per bottle. Manufactured by leading US dietary supplement producer in FDA-registered cGMP facility. Sold directly to consumers via ambrosiaz.com and through wholesale channels.
• Dr.Ergo L-Ergothioneine Bulk Powder Premium L-Ergothioneine bulk powder ingredient for healthy longevity, manufactured in FDA-registered cGMP-compliant facility with NSF cGMP and HACCP certification. Purity over 99.9% with a patented non-hygroscopic, highly stable, odorless crystal structure. Validated by two human clinical trials for skin health. Sold B2B to dietary supplement and cosmetic industries.
• Active Pharmaceutical Ingredients (API) Commercial active pharmaceutical ingredients with Drug Master Files reviewed by US FDA and EU authorities, including Benazepril, Clarithromycin, Entacavir Hydrate, Fingolimide HCl, Glimepiride, Levofloxacin, Orlistat, Prasugrel HCl, Rabeprazole Sodium, Sorafenib Tosylate, Telmisartan, Ticagrelor, and pipeline APIs. Manufacturing facilities passed FDA inspections. Sold B2B.
• Generic Drug Products (ANDA, 505(b)(2) NDA) Generic drug products including Linagliptin 5mg Tablet, Sevoflurane 250mL Bottle, and Paclitaxel Protein-Bound 100mg/Vial Powder, with active solicitation of marketing partners and licensing opportunities for global markets.
• Biosimilars Biosimilar products including Aflibercept, Adalimumab, Bevacizumab, Denosumab, Golimumab, Tocilizumab, Trastuzumab, Albipagrastim Alfa, and Bevifibatide Citrate, developed for licensing and partnership.
• Compounded Pharmaceutical Products Compounded pharmaceutical products including NAD+ IV, NMN IV, and NR IV developed, manufactured, and distributed in full compliance with US FDA 503B compounding regulations.
• Drug Product Licensing & Collaboration In- and out-licensing of pharmaceutical products worldwide including generics (ANDA and 505(b)(2) NDA), biosimilars, and new chemical entities (NCE), with active solicitation of marketing partners and licensing opportunities globally.
• Regulatory Consultation Services Regulatory consulting services including GRAS/NDI dossier preparation, US FDA filings, Canadian natural product applications, ANDA dossier preparation, DMF handling, and responses to deficiency letters for pharmaceutical and nutraceutical clients.

Quantifiable outcome

• Blood NAD+ levels increased up to 4.7-fold over baseline at 600mg daily dose
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and major.

• National University of Singapore (NUS)coreStrategic or Co-development Partner · 1 January 2020Collaboration with Professor Andrea Maier, Director of the Center for Health Longevity at NUS, on human clinical studies involving AbinoNutra NMN. Ongoing clinical trials in Taiwan, Japan, and Singapore. Professor Maier conducted multiple trials validating NMN efficacy and praised ingredient quality.
• EGT-SynbiocoreStrategic or Co-development PartnerPartnership with EGT-Synbio for L-Ergothioneine product. EGT-Synbio received FDA GRAS no-objection letter for Dr.Ergo Ergothioneine. Abinopharm collaborated on successful human clinical trials for oral L-Ergothioneine for skin health. Dr.Ergo is the second ergothioneine product to earn FDA GRAS status in the US.
• Professor Barry HalliwellmajorStrategic or Co-development PartnerCollaboration with leading expert on antioxidants and healthy longevity at NUS. Engaged in discussions about potential collaborations to advance human clinical trials of Dr.Ergo L-Ergothioneine and AbinoNutra NMN. Professor Halliwell presented at 2025 Vancouver Ergothioneine Forum.
• Shanghai Institute of Organic Chemistry, Chinese Academy of SciencescoreTechnology or IntegrationLicensed full enzymatic natural fermentation technology for L-Ergothioneine production developed by the Shanghai Institute of Organic Chemistry. Technology enables production of high-purity (over 99.9%) L-Ergothioneine.

Scale indicators7 records

Recent moves1 record

Expansion highlights5 records

Broad incumbents

• Hovione: Hovione is a global contract development and manufacturing organization specializing in APIs and drug products, with expertise in fermentation-based processes. Comparable manufacturing capabilities and regulatory services for pharmaceutical customers.
• Lonza Group: Lonza is a major global CDMO providing API manufacturing, biologics, and cell & gene services. While operating at substantially greater scale, Lonza's API and nutraceutical ingredient services overlap with Abinopharm's pharmaceutical and dietary supplement ingredient offerings.
• WuXi STA (WuXi AppTec): WuXi STA is one of the largest global CDMOs offering API manufacturing, drug product development, and regulatory services. Operates broadly across the pharmaceutical value chain where Abinopharm competes, with substantially greater scale and resources.

Direct peers

• Suanfarma: Suanfarma is a global API manufacturer and pharmaceutical ingredient supplier, including generic APIs with FDA DMF filings. Directly comparable in the generic pharmaceutical API and intermediates business where Abinopharm also competes.
• Aurea Biolabs: Aurea Biolabs develops and manufactures natural bioactive ingredients, including fermentation-derived nutraceuticals, for the supplement and cosmetic industries. Comparable as a fermentation-technology-based specialty nutraceutical ingredient supplier targeting the longevity and wellness categories.
• Elysium Health: Elysium Health is a science-driven longevity supplement company marketing branded NAD+ and cellular health products (Basis) directly to consumers. Comparable in scientific positioning, clinical trial emphasis, and DTC longevity marketing, though Elysium focuses on NR rather than NMN.
• EGT-Synbio: EGT-Synbio is both a strategic partner and direct competitor in L-Ergothioneine, holding the FDA GRAS notification for Dr.Ergo Ergothioneine alongside Abinopharm. Both produce premium L-Ergothioneine for the supplement and cosmetic markets using similar fermentation technology approaches.
• ChromaDex: ChromaDex markets Niagen, the leading branded nicotinamide riboside (NR) ingredient — a direct NAD+ precursor competitor to AbinoNutra's NMN. Both target dietary supplement brands and the longevity consumer market with clinically-validated NAD+ boosting ingredients, making them the closest direct competitor in the NAD+ precursor space.
• Metro International Biotech: Metro International Biotech (MIB) is a leading global NMN ingredient supplier and direct competitor in the pharmaceutical-grade NMN bulk market. Competes head-to-head with AbinoNutra NMN for dietary supplement and nutraceutical brand customers.

Emerging players

• Codexis: Codexis develops engineered enzymes for pharmaceutical manufacturing and biotherapeutics, including in the nutraceutical and pharmaceutical ingredient space. Comparable in enzyme-driven production approaches for high-purity ingredients, with broader focus on biocatalysis across pharmaceutical applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/abinopharm-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abinopharm, Inc.